Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

AEHR Test Systems Reports Q4 Revenue Jump

Aehr Test Systems reported fiscal fourth-quarter revenue of $18.8 million, up from $14.1 million a year earlier. The company swung to a GAAP profit of $1.4 million, or $0.04 a share, from a GAAP loss of $2.9 million, or $0.10 a share, in the prior-year quarter.

Non-GAAP net income rose to $3.6 million, or $0.11 a share, from a non-GAAP loss of $0.2 million, or $0.01 a share. Bookings hit a quarterly record of $60.7 million, while backlog at May 29 was $80.6 million. Including bookings received since then, effective backlog reached $100.6 million. Cash, cash equivalents and restricted cash climbed to $116.5 million from $37.1 million at the end of the prior quarter.

For the full fiscal year, revenue fell to $50.0 million from $59.0 million. The company posted a GAAP net loss of $7.1 million, compared with a loss of $3.9 million a year earlier. Non-GAAP net income dropped to $0.9 million from $4.6 million. Cash used in operating activities was $3.3 million for the year.

Looking ahead, Aehr projected fiscal 2027 revenue of $130 million to $150 million, versus $50.0 million in fiscal 2026. That implies growth of about 160% to 200%. Management said the forecast is supported by the $100.6 million effective backlog and expected demand from existing production programs. As a result of these announcements, the company's shares have moved 21.64% on the market, and are now trading at a price of $87.59. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS